Trigonal Injection of Botulinum Toxin A in Patients with Refractory Bladder Pain Syndrome/Interstitial Cystitis

• Tipo: Artigo em Revista Científica Internacional
• Data: 2010

Autores

Rui Pinto (Autor) FMUP; Tiago Lopes (Autor) FMUP; Bárbara Garrido (Autor) FMUP; Andre Silva (Autor) FMUP; Joao Silva (Autor) FMUP; Carlos Silva (Autor) FMUP; Célia Cruz (Autor) FMUP; Francisco Cruz (Autor) FMUP; Paulo Oliveira (Autor) FMUP

Revista

Título: European Urology

Vol. 58 Nº 3

Páginas: 360-365

ISSN: 0302-2838

Editora: Elsevier

Indexação

ISI Web of Knowledge - 136 Citações

Scopus - 155 Citações

Pubmed / Medline

Classificação Científica

FOS: Ciências médicas e da saúde > Medicina clínica

CORDIS: Ciências da Saúde > Ciências Médicas > Medicina > Urologia

Outras Informações

ID Authenticus: P-003-3CA

DOI: 10.1016/j.eururo.2010.02.031

Abstract (EN): Background: Bladder pain syndrome/interstitial cystitis (BPS/IC) is a chronic disease without an effective treatment, characterized by pain during bladder filling. Most nociceptive bladder afferents course in the trigone. Objective: To evaluate efficacy and tolerability of trigonal injection of botulinum toxin A (BoNTA) in patients with BPS/IC. Urine concentration of nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) were also evaluated. Design, setting, and participants: Women with refractory BPS/IC were included in an open, exploratory study. Intervention: Under sedation, 100 U of BoNTA (Botox) were injected in 10 trigonal sites (10 U per 1 ml saline). Retreatment was allowed 3 mo after injection. Measurements: Pain, urinary frequency, O'Leary-Sant score (OSS), quality of life, (QoL), and urodynamic testing at 1 and 3 mo and every 3 mo thereafter. Urine NGF and BDNF were assessed at the same points. Patients who were retreated were evaluated every 3 mo. Results and limitations: All patients reported subjective improvement at 1- and 3-mo follow-up. Pain, daytime and nighttime voiding frequency, OSS, and QoL improved significantly. Bladder volume to first pain and maximal cystometric capacity more than doubled. Treatment remained effective in >50% of the patients for 9 mo. Retreatment was also effective in all cases, with similar duration. A significant, transient reduction in urinary NGF and BDNF was observed. No cases of voiding dysfunction occurred. The low number of patients and the lack of a placebo arm are obvious limitations of this study. Conclusions: Trigonal injection of BoNTA is a safe and effective treatment for refractory BPS/IC.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 6